- |||||||||| toripalimab subcutaneous (JS001sc) / Shanghai Junshi Biosci
New P3 trial, Combination therapy, Metastases: First-line treatment for recurrent or metastatic non-squamous non-small cell lung cancer: A multicenter, open, randomized controlled, Phase III study comparing the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous injection) (JS001sc) and Toripalimab injection (JS001) in combination with standard chemotherapy as first-line treatment for relapsed or metastatic non-squamous non-small cell lung cancer (EUDRACT) - Jul 15, 2024
P3, N=356, Not yet recruiting,
- |||||||||| Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
Biomarker, Journal, HEOR, PD(L)-1 Biomarker, IO biomarker, Cost-effectiveness, Cost effectiveness, Metastases: Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Sep 16, 2023
From the perspective of the Chinese healthcare system, this study's findings suggested that first-line TC represents a cost-effective strategy for patients with advanced NSCLC. However, the cost-effectiveness of first-line TC varied across different subgroups when considering predictive biomarkers.
- |||||||||| Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
Journal, HEOR, PD(L)-1 Biomarker, IO biomarker, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective. (Pubmed Central) - Jun 2, 2023
With the threshold of willingness to pay we set ($37,653 per QALY), toripalimab plus chemotherapy was cost-effective in these patient populations. For patients with advanced NSCLC, toripalimab plus chemotherapy was an optimal choice as first-line treatment, regardless of histology.
- |||||||||| Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
Journal: An unusual case of immune-related gastritis in one patient receiving toripalimab therapy. (Pubmed Central) - Mar 9, 2023
Based on the improvement after toripalimab withdrawal, the authors believed that she had autoimmune gastritis caused by toripalimab. This case reminds us that correct diagnosis and proper management are critical to patients undergoing treatment with PD-1 inhibitors.
- |||||||||| Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Keytruda (pembrolizumab) / Merck (MSD)
Budget Impact Analysis of Toripalimab Versus Pembrolizumab in Previously Untreated Advanced Squamous NSCLC (Ballroom FGH) - Sep 14, 2022 - Abstract #IASLCNACLC2022IASLC_NACLC_67;
Background: The CHOICE-01 phase 3 randomized trial in previously untreated advanced non-small cell lung cancer (NSCLC) compared toripalimab or placebo plus chemotherapy (nab-paclitaxel+carboplatin [nPC] in squamous [s] and pemetrexed+platinum in non-squamous NSCLC). The 5-year budget efficiencies that can be achieved by treating 10-50% of the eligible incident US sNSCLC population with the toripalimab regimen in annually increasing increments of 10% market share at the price point of 70% of the pembrolizumab ASP are estimated to be $1.02 billion in savings.
|
